Human 3-oxo-5-alpha-steroid 4-dehydrogenase 1(SRD5A1) ELISA kit

Code CSB-EL022653HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase in six months till depleted. Apply now

Product Details

Target Name
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)
Alternative Names
SRD5A1; 3-oxo-5-alpha-steroid 4-dehydrogenase 1; SR type 1; Steroid 5-alpha-reductase 1; S5AR 1
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
0.156 ng/mL-10 ng/mL
0.039 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human SRD5A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 95  
Range % 90-102  
1:2 Average % 90  
Range % 84-95  
1:4 Average % 101  
Range % 95-106  
1:8 Average % 98  
Range % 92-104  
The recovery of human SRD5A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 89 85-93  
EDTA plasma (n=4) 92 87-96  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
10 2.017 2.063 2.040 1.795  
5 1.499 1.472 1.486 1.241  
2.5 1.004 1.064 1.034 0.789  
1.25 0.705 0.742 0.724 0.479  
0.625 0.501 0.536 0.519 0.274  
0.312 0.412 0.438 0.425 0.180  
0.156 0.347 0.361 0.354 0.109  
0 0.241 0.249 0.245    
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human SRD5A1 ELISA Kit was designed for the quantitative measurement of Human SRD5A1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 0.156 ng/mL-10 ng/mL and the sensitivity is 0.039 ng/mL .


Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene References into Functions
  1. The study described in this article shows that selected SRD5A1 and SRD5A2 polymorphisms can alter the levels of metabolic and hormonal parameters in patients with BPH. Special attention should be paid to the SDR5A2 rs12470143 polymorphism, which is associated with a change in lipid profile, as well as with the inheritance and incidence rate of MetS among these patients. PMID: 29084161
  2. Findings suggest that 5alpha-reductases (5-AR) isoenzymes could be explored as a therapeutic target for urothelial bladder cancer (UBC) with 5alpha-reductase inhibitors (5-ARI). PMID: 29187470
  3. we demonstrated that AR, 5alphaR1 and 5alphaR2 immunoreactivity in bladder urothelial carcinoma cells significantly decreased with advanced tumor grade. PMID: 28947209
  4. Studies indicate that enhanced 5alpha-reductase activity in subjects with polycystic ovary syndrome (PCOS) was associated with insulin resistance (IR) rather than obesity. PMID: 28347315
  5. Although 4-dione is the main source of 5alpha-dihydrotestosterone in human preadipocytes, production of this steroid by 5 alpha-reductase isoenzymes (SRD5A1, 2 and 3) mediates the inhibitory effect of both 4-dione and testosterone on preadipocyte differentiation. PMID: 26855069
  6. SRD5A1 small-interfering RNA knockdown led to significant increase in progesterone receptor-B nuclear import, ectopic, whereas SRD5A1 overexpression resulted in remarkable inhibition of nuclear progesterone receptor-B in P4-treated cells. Repression of SRD5A1 activated progesterone receptor-B responsive gene, whereas overexpression of SRD5A1 possessed an inhibitory effect. PMID: 26243543
  7. the genotypic distribution of 22 single nucleotide polymorphisms in SRD5A1 and SRD5A2 in a set of Spanish prostate cancer patients, were evaluated. PMID: 26174685
  8. A total of 2 SNPs in SRD5A1-rs3822430 and rs1691053-were associated with prostate-specific antigen level at diagnosis. PMID: 25960412
  9. study found SRD5A enzyme is present in spermatozoa and that its cellular content is lowered in sperm samples from varicocele patients compared to healthy subjects PMID: 25850410
  10. Results show that 5alpha-reductase type 1 was associated with intratumoral dihydrotestosterone concentrations and is an independent prognostic factor in endometrioid endometrial adenocarcinoma. PMID: 25475427
  11. In model cell lines of endometrial cancer, AKR1C2 and SRD5A1 have crucial roles in progesterone metabolism. PMID: 25463305
  12. Increased 5alphaR activity and glucocorticoid secretion rate over time are linked with the development of metabolic disease, and may represent targets for therapeutic intervention. PMID: 24986533
  13. SRD5A1 rs166050C risk variant was associated with greater prostatic exposure to androsterone PMID: 24277450
  14. Significantly higher levels of SRD5A1, AKR1C2, AKR1C3, and HSD17B10 mRNA were however found in bone metastases than in non-malignant and/or malignant prostate tissue PMID: 24244276
  15. SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment. PMID: 23499746
  16. Different effects were seen for progesterone, which significantly decreased SRD5A1 protein levels. PMID: 23183084
  17. Postmenopausal breast cancer risk associated with combined therapy may be modified by genetic variation in SRD5A1 PMID: 21947678
  18. Based on a limited selection of gene variants, no involvement of SRD5A1, SRD5A2, ESR1, ESR2 or PGR in female pattern hair loss is evident. PMID: 22509838
  19. The different expression levels of 5alpha-reductase isoenzymes may confer response or resistance to 5alpha-reductase inhibitors. PMID: 22194926
  20. Ten percent of cases and 44% of controls had the cytosine/cytosine (C/C) genotype for the SRD5A1 SNP, rs501999 indicating that this genotype may protect women against severe premenstrual symptoms. PMID: 22273344
  21. Evidence of association of two alleles for alcohol dependence (AD) is found in SRD5A1 and AKR1C3, mediating a protective effect of the minor allele at each AD marker based on the genotype of the second marker. PMID: 21323680
  22. Show positive associations of several SRD5A1 and SRD5A2 variations as independent predictors of biochemical recurrence after radical prostatectomy. PMID: 21715084
  23. Single nucleotide polymorphisms in the two isoforms of 5alpha-reductase, SRD5A1 and SRD5A2, are associated with lean patients with polycystic ovary syndrome. PMID: 21530059
  24. the dominant route of Dihydrotestosterone synthesis in castration-resistant prostate cancer bypasses testosterone, and instead requires 5alpha-reduction of androstenedione by SRD5A1 to 5alpha-androstanedione, which is then converted to DHT PMID: 21795608
  25. A statistically significant reduction of SRD5A1, SRD5A2, and CYP19A gene expression was found in the dermal papillae cells and peripheral blood mononuclear cells in idiopathic hirsutism. PMID: 21676395
  26. Pitfalls in the diagnosis of 5alpha-reductase type 2 deficiency during early infancy. PMID: 21447938
  27. High nuclear SRD5A1 expression is associated with higher prostate cancer stage. PMID: 20519274
  28. We investigated associations between single nucleotide polymorphisms in genes HSD3B1, SRD5A1/2, and AKR1C2 and prostate cancer risk PMID: 20056642
  29. Data indicate that enzymes CYP17A1 and HSD3B1 showed low expression, while AKR1C3 and SRD5A1 were abundantly expressed. PMID: 20086173
  30. role in blood pressure PMID: 11903314
  31. examination of differential methylation of isoenzyme genes in lymphocytes PMID: 11948017
  32. polymorphisms of SRD5A1 and SRD5A2 genes may not be directly associated with the development of baldness or generation of different clinical phenotypes. PMID: 12670724
  33. Loss of 5alpha-reductase type I expression is associated with metastatic prostate cancer PMID: 12738739
  34. Changes in 5alpha-reductase, 11beta-HSD1, and 20alpha/beta-HSD enzyme activities observed in polycystic ovary syndrome may contribute to increased production of cortisol and androgens. PMID: 14671189
  35. Mutant SRD5A1 isoenzyme does not seem to play a crucial role in the development of hypospadias. PMID: 14739525
  36. The direct challenge of beta-adrenergic agonists to glioma cells resulted in the rapid and transient elevation of 5alpha-R mRNA levels through the activation of the cyclic AMP (cAMP)/protein kinase A-mediated signaling pathway. PMID: 14997014
  37. Glucocorticoids and androgens differentially regulate 5alphaR1 mRNA in the rat liver. Regulation of 5alphaR1 gene is primarily at the post-transcriptional level. PMID: 15004407
  38. Candidate gene for benign prostatic hyperplasia. PMID: 15136785
  39. Expression of SRD5A1 (5alphaR1) and SRD5A2 (5alphaR2) is elevated, and expression of AKR1C1 (20alpha-HSO), AKR1C2 (3alpha-HSO3) and AKR1C3 (3alpha-HSO2) is reduced in tumorous as compared to normal breast tissue. PMID: 15212687
  40. 5alpha-reductase type 1 (5alphaR1) immunostaining is increased and 5alpha-reductase type 2(5alphaR2) immunostaining is decreased during development of prostate cancer and there is increased expression of both in recurrent and metastatic cancers PMID: 15538746
  41. Serenoa repens inhibits this enzyme in the prostate, but does not suppress prostate-specific antigen secretion in prostate cancer. PMID: 15543614
  42. 5alpha-reductase is expresed in human embryonic kidney cell line HEK293 PMID: 15792368
  43. The expression of 5alpha-reductase type I mRNA was not regulated by calcitriol in a prostate tumor cell line. PMID: 15862960
  44. SRD5A1 is abundantly transcribed in normal human genital skin fibroblasts and may play an important role in masculinization of SRD5A2-deficient males. PMID: 15941927
  45. The SRD5A1 mRNA expression is 2-fold lower than SRD5A2 in normal rat. PMID: 16818707
  46. These results suggest that intratumoral 5 alpha-dihydrotestosterone concentration is mainly determined by 5alphaRed1 and aromatase in breast carcinoma tissues. PMID: 17066438
  47. Both 5-alpha-reductase I and II are expressed in normal human prostate stromal and epithelial cells. Only 5-alpha-reductase isoenzymes of prostate epithelium are modulated by oxytocin. PMID: 18008328
  48. Hepatocyte growth factor stimulates 5alpha-R1 expression through up-regulation of the transcription factor early growth response 1 PMID: 18215136
  49. Our results demonstrate that the 5alphaR activities of either bDPCs or sDPCs are stronger than that of dermal fibroblasts, despite the fact that the major steroidogenic activity is attributed to 17beta-HSD rather than 5alphaR among the three cell types. PMID: 18258185
  50. Testosterone 5-alpha-Reductase deficiency is associated with gender identity PMID: 18422030

Show More

Hide All

Subcellular Location
Microsome membrane; Multi-pass membrane protein. Endoplasmic reticulum membrane; Multi-pass membrane protein.
Protein Families
Steroid 5-alpha reductase family
Tissue Specificity
Liver and prostate (at a low level).
Database Links

HGNC: 11284

OMIM: 184753

KEGG: hsa:6715

STRING: 9606.ENSP00000274192

UniGene: Hs.552

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1